1-8 of 8
Gustavo Fonseca
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study

Jonathan W. Friedberg, Carrie A. Thompson, Marek Trněný, Franck Morschhauser, Gilles Salles, Patrick M. Reagan, Mark Hertzberg, Piotr Smolewski, Huilai Zhang, Catherine Thieblemont, Bei Hu, Gustavo Fonseca, Won-Seog Kim, Maurizio Martelli, Amitkumar Mehta, Avrita Campinha-Bacote, Mark Yan, Jamie Hirata, Matthew Sugidono, Calvin Lee, Jeff P. Sharman
Journal: Blood
Blood (2022) 140 (Supplement 1): 6623–6626.
https://doi.org/10.1182/blood-2022-157761
Published: 2022
Journal Articles

Efficacy and Safety of Umbralisib, Ublituximab (U2), and U2 Plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

John M. Burke, Gustavo Fonseca, Wojciech Jurczak, Jason Melear, Miguel Islas-Ohlmayer, James A Reeves, Parameswaran Venugopal, Tomasz Wróbel, Don Stevens, John M. Pagel, Jerome Goldschmidt, Hari P. Miskin, Peter Sportelli, Owen A. O'Connor, Nilanjan Ghosh
Journal: Blood
Blood (2021) 138 (Supplement 1): 527.
https://doi.org/10.1182/blood-2021-151054
Published: 2021
Journal Articles

The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial

Julio C. Chavez, Neta Goldschmidt, Felipe Samaniego, Tomasz Wrobel, Federica Cavallo, Gustavo Fonseca, Sung-Soo Yoon, Lubos Drgona, Eliza Hawkes, Itai Levi, Hari P. Miskin, Peter Sportelli, Owen A. O'Connor, Nathan H. Fowler, Pier Luigi Zinzani
Journal: Blood
Blood (2021) 138 (Supplement 1): 45.
https://doi.org/10.1182/blood-2021-147425
Published: 2021
Journal Articles

Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure

David S Siegel, MD PhD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD PhD, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V Matous, MD, Kevin Song, MD, Christopher S. Seet, MD, Giampaolo Talamo, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand Anz, MD, Gustavo Fonseca, Donna Reece, Amit Agarwal, MD PhD, Weiyuan Chung, Faiza Zafar, MPAS, Nizar Bahlis, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3271.
https://doi.org/10.1182/blood-2018-99-111920
Published: 2018
Journal Articles

Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab

William E. Pierceall, Nizar Bahlis, MD, David S Siegel, MD PhD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD PhD, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V Matous, MD, Kevin Song, MD, Christopher S. Seet, MD, Giampaolo Talamo, Shanti Srinivas, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand Anz, Gustavo Fonseca, Donna Reece, Weiyuan Chung, Natalya Serbina, Faiza Zafar, MPAS, Amit Agarwal, MD PhD, Anjan Thakurta, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2012.
https://doi.org/10.1182/blood-2018-99-111554
Published: 2018
Journal Articles

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

Xiaozhong Qian, Kathryn Newhall, PhD, Mark Tometsko, Chad Bjorklund, Jianglin Ma, Nizar J. Bahlis, MD, David Siegel, MD PhD, Gary J. Schiller, MD, Christy Samaras, Michael Sebag, MD PhD, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V. Matous, MD, Kevin W Song, MD, Christopher S. Seet, Giampaolo Talamo, Shanthi Srinivas, Mirelis Acosta-Rivera, Michael Bar, Donald Quick, Bertrand Anz, Gustavo Fonseca, Donna Reece, MD FRCP(C), Jorge Mouro, MS, Amit Agarwal, MD PhD, Faiza Zafar, MPAS, Anjan Thakurta, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1888.
https://doi.org/10.1182/blood.V130.Suppl_1.1888.1888
Published: 2017
Journal Articles

Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure

David Siegel, MD PhD, Gary J. Schiller, MD, Christy Samaras, Michael Sebag, MD PhD, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V. Matous, MD, Kevin W Song, MD, Christopher S. Seet, Giampaolo Talamo, Shanthi Srinivas, Mirelis Acosta-Rivera, Michael Bar, Donald Quick, Bertrand Anz, Gustavo Fonseca, Donna Reece, MD FRCP(C), Jorge Mouro, MS, Amit Agarwal, MD PhD, Faiza Zafar, MPAS, Max Qian, Anjan Thakurta, PhD, Nizar J. Bahlis, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1811.
https://doi.org/10.1182/blood.V130.Suppl_1.1811.1811
Published: 2017
Journal Articles

Phase I/II Study of Oral Fodosine TM , a PNP Inhibitor in Refractory Cutaneous T-Cell Lymphoma Patients.

Madeleine Duvic, MD, Debra Breneman, MD, Maureen Cooper, MD, Gustavo Fonseca, MD, J. Claude Bennett, MD, J. Michael Kilpatrick, PhD, Shanta Bantia, PhD
Journal: Blood
Blood (2005) 106 (11): 2683.
https://doi.org/10.1182/blood.V106.11.2683.2683
Published: 2005